1. A 38-year-old man with opioid use disorder maintained on buprenorphine-naloxone 16 mg/4 mg daily is admitted for emergency surgery requiring general anesthesia and postoperative pain management. The anesthesiologist and pain team discuss opioid analgesic strategy. Which of the following correctly identifies the pharmacodynamic challenge and the most appropriate approach?
A) Buprenorphine's high affinity and slow koff prevent effective competitive displacement of it by morphine -- the correct approach is to discontinue buprenorphine 24 hours before surgery and allow sufficient washout before initiating full agonist analgesia
B) Morphine is a partial agonist with lower intrinsic efficacy than buprenorphine, so dose escalation will not overcome buprenorphine occupancy -- the correct approach is to use fentanyl, a full agonist with higher intrinsic efficacy, which can effectively compete with and displace buprenorphine
C) The receptor reserve available to morphine is substantially reduced by high buprenorphine occupancy -- the correct approach is to use a non-competitive opioid analgesic that bypasses the mu-receptor entirely, such as tramadol acting through its serotonin-norepinephrine reuptake inhibition component
D) Escalating morphine doses high enough to partially overcome buprenorphine occupancy through mass action is feasible and safe -- with careful respiratory monitoring, suprapharmacological morphine doses will displace buprenorphine and provide adequate analgesia without exceeding the respiratory safety margin
E) Buprenorphine's high mu-opioid receptor affinity and slow dissociation rate substantially reduce the number of receptors available for exogenous opioid analgesia; the most appropriate strategies include continuing buprenorphine perioperatively (which provides its own partial analgesia) combined with maximized multimodal non-opioid analgesia (NSAIDs, acetaminophen, ketamine, regional anesthesia), and if opioids are needed, using very high doses of full agonists with intensive monitoring, recognizing that standard opioid doses will be inadequate
ANSWER: E
Rationale:
Perioperative management of patients on buprenorphine maintenance therapy is one of the most pharmacodynamically challenging scenarios in acute pain management. Buprenorphine's exceptional mu-opioid receptor affinity (sub-nanomolar Kd) and slow receptor dissociation rate (small koff) mean it continuously occupies the vast majority of mu-opioid receptors. Any full opioid agonist administered for surgical pain must compete with buprenorphine for the small fraction of unoccupied receptors, and standard analgesic doses are typically insufficient. Multiple strategies are used based on current pain society guidelines: first, buprenorphine itself provides partial analgesia and should generally be continued rather than stopped (abrupt discontinuation risks relapse and does not immediately free receptors due to the slow koff); second, maximizing non-opioid analgesic modalities (NSAIDs, acetaminophen, ketamine infusion, regional nerve blocks, epidural analgesia) reduces opioid requirements; third, when opioids are necessary, substantially higher than standard doses of full agonists are required, with intensive monitoring for delayed respiratory depression as buprenorphine gradually leaves receptors.
Option A: Option A is incorrect -- 24-hour discontinuation is insufficient given buprenorphine's slow receptor dissociation; moreover, discontinuation risks relapse to illicit opioid use and is not currently recommended as routine practice.
Option B: Option B is incorrect -- morphine is a full mu-opioid agonist, not a partial agonist; fentanyl does not have meaningfully higher intrinsic efficacy than morphine at mu receptors -- both are full agonists and the challenge is receptor availability, not intrinsic efficacy differences between full agonists.
Option C: Option C is incorrect -- tramadol's serotonin-norepinephrine reuptake inhibition component provides insufficient analgesia for surgical pain; there is no non-competitive opioid analgesic that bypasses mu receptors entirely for acute severe pain.
Option D: Option D is incorrect -- while dose escalation of opioids is sometimes necessary, characterizing suprapharmacological morphine dosing as safe without intensive monitoring dramatically understates the risk; buprenorphine occupancy does not protect against respiratory depression from the fraction of opioid that does bind available receptors.
2. A 24-year-old woman with seasonal allergic rhinitis uses cetirizine 10 mg daily. She asks whether taking a higher dose -- 20 mg daily -- during peak pollen season would provide significantly better symptom control. Which of the following pharmacodynamic principle best informs the answer?
A) Cetirizine is an inverse agonist at H1 receptors -- it not only blocks histamine-driven signaling but also reduces constitutive H1 receptor activity below baseline; at the standard 10 mg dose, cetirizine achieves near-maximal H1 receptor occupancy in peripheral tissues (approximately 70-80% occupancy) and substantially reduces both histamine-driven and constitutive H1 signaling; doubling the dose produces only marginal additional receptor occupancy on the steep portion of the saturation curve, and the pharmacodynamic benefit is minimal relative to the increased cost and potential for side effects
B) Cetirizine is a competitive antagonist at H1 receptors -- higher doses would shift the dose-response curve for histamine further rightward, providing meaningfully greater symptom suppression during high-pollen exposure when histamine levels are elevated; doubling the dose is pharmacodynamically rational and clinically appropriate during peak season
C) Cetirizine is a non-competitive antagonist at H1 receptors -- it permanently reduces the Emax of histamine's allergic response; the 10 mg dose already achieves maximum non-competitive blockade and higher doses provide no additional benefit because non-competitive Emax reduction cannot be increased further
D) Cetirizine is a partial agonist at H1 receptors -- at low doses it produces weak histamine-like proinflammatory effects before switching to net antagonism at higher doses; increasing to 20 mg ensures the drug remains in the net-antagonist range throughout the high-allergen season
E) Cetirizine acts at histamine N-methyltransferase rather than directly at H1 receptors -- it reduces histamine metabolism, paradoxically increasing histamine availability; higher doses would worsen symptoms during peak pollen season by further increasing histamine concentrations at H1 receptors
ANSWER: A
Rationale:
Cetirizine is an established inverse agonist at H1 receptors, preferentially stabilizing the inactive H1 receptor conformation and reducing both histamine-driven and constitutive H1 signaling. The pharmacokinetic-pharmacodynamic relationship for cetirizine is well-characterized: at 10 mg, cetirizine achieves approximately 70-80% H1 receptor occupancy in skin and nasal mucosa, which corresponds to near-maximal suppression of histamine-induced wheal and flare responses in challenge studies. The relationship between cetirizine dose and H1 occupancy follows a saturable binding curve -- at 70-80% occupancy, the curve is already in its upper, flatter portion. Doubling the dose to 20 mg would increase receptor occupancy by perhaps 5-10% (from ~75% to ~80-85%), producing negligible additional pharmacodynamic benefit. This is the clinical pharmacodynamic basis for why major antihistamine guidelines do not routinely recommend doses above 10 mg for cetirizine in adults -- the dose-response curve has already reached its plateau at standard dosing. The additional sedation risk (cetirizine has mild CNS penetration) further disfavors dose escalation.
Option B: Option B is incorrect -- cetirizine is an inverse agonist, not merely a competitive antagonist; and while more competitive antagonist would theoretically shift the histamine curve, the relevant pharmacodynamic ceiling issue is receptor occupancy saturation at standard doses.
Option C: Option C is incorrect -- cetirizine is not a non-competitive antagonist; it acts competitively at the H1 orthosteric site (while also acting as an inverse agonist on constitutive activity).
Option D: Option D is incorrect -- cetirizine has no agonist component at any dose; H1 antihistamines do not exhibit biphasic agonist-then-antagonist behavior.
Option E: Option E is incorrect -- cetirizine acts directly at H1 receptors, not at histamine-metabolizing enzymes; it does not increase histamine concentrations.
3. A 61-year-old woman with advanced androgen-receptor positive adenocarcinoma initially responds to enzalutamide, a competitive androgen receptor (AR) antagonist, but develops resistance after 18 months. Tumor genomic sequencing reveals an F877L point mutation in the AR ligand-binding domain. In vitro studies show that enzalutamide now activates rather than inhibits AR transcriptional activity in cells expressing the mutant receptor. Which of the following best explains this pharmacodynamic phenomenon?
A) The F877L mutation increases the binding affinity of enzalutamide for the mutant AR, producing receptor overactivation through enhanced occupancy at concentrations that previously produced only partial blockade
B) The F877L mutation prevents enzalutamide from entering the cell by altering the lipid composition of the tumor cell membrane, so enzalutamide accumulates extracellularly and activates surface-expressed AR splice variants
C) The F877L mutation alters the conformational response of the AR ligand-binding domain to enzalutamide binding -- instead of stabilizing the inactive receptor conformation (antagonist behavior), enzalutamide binding to the mutant receptor now stabilizes the active transcriptional conformation, converting enzalutamide from a competitive antagonist to a functional agonist at the mutant AR; this is a clinically important example of mutation-induced agonist switch driving antiandrogen resistance
D) The F877L mutation converts the AR from a nuclear receptor to a GPCR-coupled receptor that signals through cAMP rather than direct DNA binding, making enzalutamide's competitive antagonism at the ligand-binding domain irrelevant to transcriptional output
E) The mutation produces constitutive AR activation independent of ligand binding -- enzalutamide cannot produce transcriptional activation because it still binds the receptor; the apparent agonism reflects relief of tonic inhibitory signaling when enzalutamide displaces endogenous antagonists from the mutant AR
ANSWER: C
Rationale:
The F877L AR mutation is a clinically important example of acquired resistance to antiandrogen therapy mediated by a pharmacodynamic mechanism -- mutation-induced agonist switch. Enzalutamide is a competitive AR antagonist that works by binding the AR ligand-binding domain and stabilizing an inactive receptor conformation that prevents AR nuclear translocation and transcriptional activation. In the wild-type AR, enzalutamide binding locks the receptor in an inactive state -- it is a functional antagonist. The F877L mutation (phenylalanine to leucine at position 877 in the ligand-binding domain) alters the geometry of the binding pocket such that when enzalutamide binds, it induces a different conformational change -- one that mimics the agonist-bound active conformation rather than the antagonist-bound inactive conformation. The receptor now undergoes nuclear translocation and drives transcription of androgen-responsive genes in response to enzalutamide. From a two-state receptor model perspective, enzalutamide's selectivity for R (inactive) over R* (active) is reversed by the mutation -- the drug now preferentially stabilizes R* at the mutant receptor, converting it to a functional agonist. This resistance mechanism has been identified in prostate cancer patients treated with enzalutamide and provides rationale for next-generation AR antagonists designed to maintain antagonist activity at common resistance mutations.
Option A: Option A is incorrect -- increased binding affinity does not convert an antagonist to an agonist; affinity and intrinsic efficacy are independent properties.
Option B: Option B is incorrect -- enzalutamide is a small molecule that enters cells through passive diffusion; it does not act on surface receptors and membrane composition changes are not the mechanism of this resistance.
Option D: Option D is incorrect -- the AR remains a nuclear receptor in cancer cells with F877L mutation; it does not convert to GPCR signaling.
Option E: Option E is incorrect -- constitutive AR activation independent of ligand would not produce ligand-dependent (enzalutamide-induced) transcription; the mutation specifically alters how enzalutamide binding is transduced, not whether the receptor can signal constitutively.
4. A 52-year-old man is treated with propranolol 80 mg twice daily for hypertension and paroxysmal SVT. After three years of stable therapy he abruptly discontinues propranolol without medical advice. Within 48 hours he develops severe angina, tachycardia, and is subsequently found to have an acute myocardial infarction. Which of the following best explains the pharmacodynamic mechanism underlying this outcome?
A) Abrupt propranolol discontinuation allows previously blocked beta-adrenergic receptors to resume normal sensitivity to catecholamines -- the rebound reflects simply the loss of pharmacological blockade with no change in underlying receptor pharmacodynamics
B) Propranolol is an irreversible beta-adrenergic antagonist that permanently blocked all beta receptors for three years -- abrupt discontinuation allowed synthesis of new unblocked receptors that were hypersensitive due to their naïve, never-before-stimulated state
C) Propranolol's abrupt discontinuation caused acute beta-receptor downregulation -- the receptors that had been chronically blocked suddenly internalized in response to the surge of catecholamines that were previously unable to reach them
D) Chronic propranolol-mediated beta-receptor blockade caused compensatory upregulation of beta-adrenergic receptors -- the cardiac and vascular myocytes responded to perceived catecholamine deficiency by increasing receptor density and sensitivity; when propranolol was abruptly withdrawn, the supranormal number of upregulated, hypersensitive beta receptors were suddenly exposed to normal circulating catecholamines, producing an exaggerated adrenergic response -- tachycardia, hypertension, increased myocardial oxygen demand, and coronary vasospasm -- precipitating acute myocardial ischemia
E) The clinical presentation reflects propranolol accumulation and toxicity -- abrupt discontinuation caused rebound sympathomimetic effects through propranolol's active metabolite 4-hydroxypropranolol, which acts as a partial beta-agonist when the parent drug is no longer present to competitively block it
ANSWER: D
Rationale:
Beta-blocker withdrawal syndrome is a well-characterized clinical phenomenon with a clear pharmacodynamic mechanism rooted in receptor upregulation. Chronic beta-adrenergic receptor blockade by propranolol creates a state of perceived catecholamine deficiency at the receptor level -- the receptors are chronically unoccupied by their endogenous agonist (norepinephrine and epinephrine) because the competitive antagonist is blocking them. The cellular response to sustained receptor inactivity is compensatory upregulation: receptor density increases through reduced internalization and increased synthesis, and post-receptor signal transduction may also be sensitized. After three years of therapy, beta-receptor density in cardiac and vascular tissue is substantially higher than baseline. When propranolol is abruptly withdrawn, circulating catecholamines suddenly have access to a supranormal number of hypersensitive beta receptors. The result is an exaggerated adrenergic response: tachycardia (increased heart rate), increased contractility, increased myocardial oxygen demand, and potentially coronary vasospasm -- all of which can precipitate acute myocardial ischemia in a patient with underlying coronary disease. This is why beta-blockers must always be tapered gradually, particularly in patients with coronary artery disease, and why abrupt withdrawal is a medical emergency in such patients.
Option A: Option A is incorrect -- the rebound is not simply loss of blockade; receptor upregulation means the response to catecholamines is supranormal, not merely restored to baseline.
Option B: Option B is incorrect -- propranolol is a reversible competitive antagonist, not irreversible; it does not permanently block receptors.
Option C: Option C is incorrect -- abrupt discontinuation causes receptor exposure to catecholamines and upregulated receptor stimulation, not acute receptor downregulation; downregulation is the response to chronic agonist exposure, not antagonist withdrawal.
Option E: Option E is incorrect -- 4-hydroxypropranolol is an active metabolite with beta-blocking activity, not beta-agonist activity; it does not produce the withdrawal syndrome described.
5. A 45-year-old man with treatment-resistant schizophrenia is started on clozapine after two failed trials of first-generation antipsychotics (haloperidol) and one failed trial of a second-generation antipsychotic (risperidone). His psychiatrist explains that clozapine works differently from other antipsychotics. Which of the following best describes the pharmacodynamic basis for clozapine's superior efficacy in treatment-resistant schizophrenia compared to drugs that primarily target D2 receptors?
A) Clozapine's lower D2 occupancy produces less extrapyramidal side effects than haloperidol, allowing dose escalation to levels that achieve equivalent D2 blockade with better tolerability -- its efficacy is therefore quantitatively rather than qualitatively different
B) Clozapine's therapeutic superiority in treatment-resistant schizophrenia arises from its broad receptor profile -- it is a low-affinity, rapidly dissociating D2 antagonist combined with high-affinity antagonism or inverse agonism at multiple other receptors including 5-HT2A, 5-HT2C, D4, D1, muscarinic M1/M4, H1, and alpha-1 adrenergic receptors; the combination of weak D2 blockade with strong serotonergic, dopaminergic D4, and other receptor modulation addresses the neurobiological complexity of treatment-resistant schizophrenia that pure D2 blockade cannot resolve
C) Clozapine is actually a full D2 agonist at the subset of D2 receptors located in prefrontal cortex, producing pro-cognitive effects through cortical dopamine enhancement while simultaneously blocking D2 receptors in mesolimbic pathways -- this regional receptor selectivity produces antipsychotic efficacy with cognitive benefit
D) Clozapine's lower D2 occupancy is a pharmacokinetic artifact -- its high lipophilicity causes preferential distribution to limbic rather than striatal brain regions, producing antipsychotic-equivalent D2 blockade in mesolimbic areas at lower measured plasma concentrations
E) Treatment-resistant schizophrenia is pharmacodynamically defined as a disease where D2 receptors have mutated to have lower affinity for standard D2 antagonists -- clozapine's unique efficacy reflects its retained high affinity for the mutant D2 receptors that no longer bind haloperidol or risperidone
ANSWER: B
Rationale:
Clozapine's pharmacodynamic profile is fundamentally different from first-generation and most second-generation antipsychotics in a way that explains its unique efficacy. Standard antipsychotics such as haloperidol are high-affinity, slowly-dissociating D2 antagonists that achieve 70-90% D2 receptor occupancy at therapeutic doses. Clozapine, by contrast, is a low-affinity, rapidly-dissociating (fast-off) D2 antagonist -- it achieves only 20-60% D2 occupancy at therapeutic doses and dissociates from D2 receptors so rapidly that endogenous dopamine can compete effectively (the fast-off hypothesis). This fast-off kinetics may explain the very low extrapyramidal side effect burden. However, clozapine simultaneously has high-affinity antagonist or inverse agonist activity at a remarkably broad range of other receptors: 5-HT2A and 5-HT2C (serotonin), D4 (dopamine D4), D1 (dopamine D1), M1 and M4 (muscarinic), H1 (histamine), and alpha-1 adrenergic receptors. The combined modulation of this complex receptor network -- particularly the 5-HT2A/D2 ratio -- is thought to engage neurotransmitter circuits in prefrontal cortex and limbic regions that pure D2 blockade cannot access. Treatment-resistant schizophrenia may involve pathological alterations in glutamatergic, GABAergic, and serotonergic systems beyond the dopaminergic dysfunction that D2-centric drugs target, and clozapine's broad profile addresses this complexity.
Option A: Option A is incorrect -- clozapine's superiority is not simply a tolerability-enabled dose advantage; it produces qualitatively different outcomes in treatment-resistant patients at D2 occupancy levels that would be subtherapeutic for standard antipsychotics.
Option C: Option C is incorrect -- clozapine is not a D2 agonist in any brain region; it is consistently a D2 antagonist/partial agonist with low occupancy.
Option D: Option D is incorrect -- clozapine's regional brain distribution does not account for antipsychotic-equivalent D2 blockade; its limbic selectivity is modest and pharmacokinetically real but does not explain its unique efficacy in treatment-resistant disease.
Option E: Option E is incorrect -- treatment-resistant schizophrenia is not defined by D2 receptor mutations; it is defined clinically as failure to respond to adequate trials of standard antipsychotics.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.